Pharmaceutical Executive-01-01-2022

China Invests in Building Biotech

January 11, 2022

Features

42

1

Government-led programs aim to attract scientists and offer resources to growing industry.

Branding Takes on a New Look

January 11, 2022

Features

42

1

Pharma moves beyond promoting products to increase recognition of company names.

Addressing Access Burdens

January 11, 2022

Features

42

1

Employer-sponsored health plans create an increasingly cloudy path to access.

Meeting the Patient—Virtually

January 11, 2022

Features

42

1

Standard for reaching patients shifts with influx of new technology in post-COVID world.

The Age of Influence

January 11, 2022

Features

42

1

Pandemic lockdowns push pharma into brand-new era of social engagement.

Boosting Immunotherapies

January 11, 2022

Features

42

1

Oncology and rare disease are ready to reap the benefits of COVID drug development.

Pharma’s Psychedelic Experience

January 11, 2022

Features

42

1

Growing evidence supports psychoactive substances can successfully treat mental issues.

Supply Chain Procurement

January 11, 2022

Features

42

1

As borders shut down during the pandemic, pharma learned some lessons about sourcing.

Our View on 2022: Pharm Exec’s Annual Industry Outlook

January 11, 2022

42

1

Supply chain issues, psychedelic medicines, immunotherapies, social engagement, telemedicine, access barriers, corporate branding, and the rise of Chinese biotech are industry topics that deserve a closer look as we head into the future.

Breaking New Ground in Biopharma

January 11, 2022

Executive Profile

42

1

Myrtle Potter is no stranger to overcoming adversity. As CEO of Sumitovant Biopharma, she has used her entrepreneurship, determination, and inclusive attitude to help her persevere and achieve her highest goals while overseeing five companies—Myovant, Urovant, Enzyvant, Altavant, and Spirovant.